Accutane iPLEDGE Program Tops CDER Ombudsman’s 2006 Complaint List
Executive Summary
The most frequent complaint to the Center for Drug Evaluation & Research Ombudsman's office in 2006 concerned implementation of the iPLEDGE program, the office said in its annual report, issued Feb. 28
You may also be interested in...
Teratogenic Drugs Need Better Risk Plans; FDA Seeks Advice From Advisory Cmte.
Recent scientific literature shows that while most women who take drugs that are known to cause birth defects have heard about the risks, they don’t necessarily understand them or follow medical advice on not getting pregnant.
Can A REMS Block A Generic? Thalomid Could Be Early Test
Celgene's arguments against generics of Thalomid (thalidomide) offer another example of the potentially vast consequences of FDA's new safety powers: The firm is arguing that the complexity of its risk management plan precludes the approval of alternate versions of the product
Can A REMS Block A Generic? Thalomid Could Be Early Test
Celgene's arguments against generics of Thalomid (thalidomide) offer another example of the potentially vast consequences of FDA's new safety powers: The firm is arguing that the complexity of its risk management plan precludes the approval of alternate versions of the product